UroToday

SUO 2025: Trials in Progress - The GAIN Trial (ALLIANCE A032303): Gemcitabine Alternating with Intravesical BCG Randomization Against BCG Alone for Patients with Recurrent ...

(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Eugene Pietzak discussing the GAIN trial assessing gemcitabine ...
UroToday

ESMO 2025: IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

(UroToday.com) The 2025 ESMO annual meeting featured a Presidential Symposium session and a presentation by Dr. Thomas B. Powles discussing results from IMvigor011, a phase 3 trial of ctDNA-guided ...
UroToday

SUO 2025: Efficacy of Rucaparib vs Physician’s Choice in Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer by Age: Results from the TRITON3 Study

SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.
UroToday

ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations ...

San Francisco, California (UroToday.com) The PROfound Study is the first positive randomized Phase 3 study in a molecularly-defined population of patients with metastatic castration-resistant prostate ...
UroToday

ESMO 2025: Efficacy of Cabozantinib and Nivolumab in Cluster 1/2 Metastatic Clear Cell Renal Cell Carcinoma: Results from OPTIC RCC, a Phase II Trial of a Novel RNAseq-based ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany, between October 17 th and 21 st, 2025, was host to a renal and urothelial carcinoma ...
UroToday

ESMO 2025: Neoadjuvant Darolutamide + ADT for High/very-High Risk Locally Advanced Prostate Cancer: A Multi-Center, Open Label, Single Arm, Phase 2 Trial

(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Kaiwei Yang discussing a phase 2 trial assessing neoadjuvant darolutamide + ADT for ...